Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2009.21.8198 on April 20 2009

Journal of Clinical Oncology, Vol 27, No 15 (May 20), 2009: pp. 2572-2573
© 2009 American Society of Clinical Oncology.

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atkins, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atkins, C. D.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CORRESPONDENCE

CA 19-9 and Lewis Antigens in Pancreatic Cancer

Carl D. Atkins

Rockville Centre, NY

To the Editor:

Berger et al1 report on the relationship between postresection CA 19-9 levels and survival in patients with pancreatic cancer treated with adjuvant chemoradiotherapy in the Radiation Therapy Oncology Group 9704 trial. In this analysis, the authors assigned a CA 19-9 level of 0 to patients whose red cell phenotyping for both Lewis A and B antigens was reported to be negative. They based this decision on a 1987 study by Tempero et al,2 which they interpreted to show that "by definition, [such patients] do not have the ability to secrete CA 19-9 into their serum"1; However, Tempero et al examined, in all, twenty patients, only three of whom were Lewis antigen A and B negative. The fact that none of these three patients had elevated CA 19-9 levels (they were not 0, but 4, 10, and 14) does not prove that all patients who lack Lewis antigens lack the ability to secrete CA 19-9. Referring to a table of binomial distributions tells us that the 95% CI for the proportion of patients with elevated CA 19-9 when none are found in a sample of three is 0% to 71%.3 Our usual statistical guidelines do not even permit us to suggest that Lewis antigen–negative patients are less likely to have high CA 19-9 levels than to have low levels.

The zeroing out of Lewis antigen–negative patients is all the more disturbing given the discordance Berger et al1 note between the 34% incidence of such patients in their study and the 5% to 10% incidence in the general population.

Berger et al1 appear to have missed an opportunity to further our understanding of the correlation between Lewis antigen blood group and CA 19-9 by failing to replicate the work of Tempero et al2 with adequate quality controls. As a result, they may have confounded the results of their study of the relationship between postresection CA 19-9 levels and survival in pancreatic carcinoma.

AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

REFERENCES

1. Berger AC, Garcia M Jr, Hoffman JP, et al: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 26:5918–5922, 2008.[Abstract/Free Full Text]

2. Tempero MA, Uchida E, Takasaki H, et al: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47:5501–5503, 1987.[Abstract/Free Full Text]

3. Diem K, and Lenter C. Scientific Tables, ed 7. Basel, Switzerland: Ciba-Geigy, 1970. p.85.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • Reply to C.D. Atkins
    Adam C. Berger, John P. Hoffman, Kathryn Winter, William Regine, Howard Safran, Ross Abrams, and Christopher Willet
    JCO 2009 27: 2573 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
A. C. Berger, J. P. Hoffman, K. Winter, W. Regine, H. Safran, R. Abrams, and C. Willet
Reply to C.D. Atkins
J. Clin. Oncol., May 20, 2009; 27(15): 2573 - 2573.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Atkins, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atkins, C. D.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online